Biological
23-valent pneumococcal capsular polysaccharide vaccine clinical trials
Also written PPV23 and Pneumo 23.
- studies test it
- 42
- open now
- 4
- in phase 3
- 12
- first study started
- 2000
Keep track of what changes. Save the 23-valent pneumococcal capsular polysaccharide vaccine studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Combined with it in one product
- V110
- 2
Studies by the year they started
42 studies that test it; most in 2014 (7)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2003 | 1 |
| 2005 | 1 |
| 2007 | 5 |
| 2008 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 1 |
| 2014 | 7 |
| 2015 | 4 |
| 2016 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 6 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 4
- Phase 2
- 7
- Phase 3
- 12
- Phase 4
- 17
- No phase
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 17 · Other 25
Merck Sharp & Dohme LLC (5) · GlaxoSmithKline (3) · Assistance Publique - Hôpitaux de Paris (2) · China National Biotec Group Company Limited (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · CanSino Biologics Inc. (1) · Ab&B Bio-tech Co., Ltd.JS (1) · Universitaire Ziekenhuizen KU Leuven (1)
Often tested with
Tested in the same studies.
Pneumococcal Vaccines (23) · 13-valent pneumococcal vaccine (9) · Heptavalent Pneumococcal Conjugate Vaccine (2) · Vi polysaccharide vaccine, typhoid (2) · Diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine (1) · ASP3772 (1) · Intramuscular Route of Administration (1) · Meningococcal Vaccines (1)
Studies
Open first, then newest update. How each study uses 23-valent pneumococcal capsular polysaccharide vaccine is read from its arms, and is right about nine times in ten.
Testing it · 42
- Preoperative Pneumococcal and Influenza Vaccination to Prevent Postoperative Pulmonary Infection in Patients Undergoing Lung Resection for Pulmonary Nodules or Lung CancerNot yet recruitingPhase 4The First Affiliated Hospital of Guangzhou Medical UniversityNCT07885540Written as 23-valent pneumococcal polysaccharide vaccine
- Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury PatientsRecruitingPhase 2University of California, DavisNCT02232191Written as Pneumovax-23
- Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a LymphomaRecruitingPhase 4Poitiers University HospitalNCT04460235Written as Prevenar 13 + Pneumovax 23
- A Clinical Trial to Evaluate the Immunogenicity and Safety of the 23-valent Pneumococcal Polysaccharide Vaccine in Healthy PeopleRecruitingPhase 3Aimei Vacin BioPharm (Zhejiang) Co., Ltd.NCT06044077Written as 23-valent pneumococcal polysaccharide vaccine
- A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component)CompletedPhase 2/3CanSino Biologics Inc.NCT06708286Written as PPV23
- Clinical Trial of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Chinese Population Aged 2 Years and AboveCompletedPhase 1Ab&B Bio-tech Co., Ltd.JSNCT05815264Written as 23-valent pneumococcal polysaccharide vaccine
- Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus ErythematosusCompletedPhase 2/3Assistance Publique - Hôpitaux de ParisNCT00611663Written as Prevenar® and Pneumo23®
- Polysaccharide Antibody Response StudyCompletedPhase 4Universitaire Ziekenhuizen KU LeuvenNCT02429531Written as Pneumovax 23 (Sanofi Pasteur MSD)
- A Study to Evaluate Pneumococcal Polysaccharide Vaccine Effectiveness in Children With Type 1 DiabetesCompletedPhase 4Mayo ClinicNCT04481243Written as Pneumovax 23- pneumococcal polysaccharide
- Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for CIBDTerminatedPhase 2Centre Hospitalier Universitaire de Saint EtienneNCT02255227Written as Pneumo 23
- Immune Response After Pneumococcal Vaccination in Patient With Chronic Lymphocytic LeukemiaCompletedPhase 4Region Örebro CountyNCT05316831Written as PPSV23
- Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic DiseaseCompletedPhase 4Region SkaneNCT03762824Written as 23-valent pneumococcal polysaccharide vaccine
- Persistent Readiness Through Early Prediction Immunization StudyCompletedEarly Phase 1Texas A&M UniversityNCT05346302Written as Pneumovax 23
- PREVENTING PNEUMOcoccal Disease Through Vaccination (Study 2)Status unknownPhase 4Liverpool School of Tropical MedicineNCT04974294Written as PPV23
- Vaccinating Children After ChemotherapyCompletedPhase 4Canadian Immunization Research NetworkNCT02447718Written as Pneumovax® 23
- Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female SubjectsCompletedPhase 1Affinivax, Inc.NCT04265911Written as PPSV23 (subcutaneous)
- A Clinical Trial to Evaluate the Safety and Immunogenicity of PPV23 Vaccine Revaccinated in 60-70 Years OldCompletedPhase 4China National Biotec Group Company LimitedNCT04700618Written as 23-valent pneumococcal polysaccharide vaccine
- A Clinical Trial to Evaluate the Immunogenicity and Safety of PPV23 Vaccine Revaccinations in the ElderlyCompletedPhase 4China National Biotec Group Company LimitedNCT04701788Written as 23-valent pneumococcal polysaccharide vaccine
- Evaluation of the Safety and Immunogenicity of Sequential Administration of Prevnar 13™ and Pneumovax™ 23 in Healthy Participants 50 Years of Age and Older (V110-029)CompletedPhase 3Merck Sharp & Dohme LLCNCT02225587Written as Pneumovax™ 23
- Open Randomized Trial Evaluating Four Anti-pneumococcal Vaccine Strategies With Fractionated Doses of Non Conjugate Polysaccharide Vaccine to Prevent Hyporesponse in Healthy VolunteersCompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT02279589Written as Pneumo 23® 0,5
See all 42 studies that test 23-valent pneumococcal capsular polysaccharide vaccine →
Given in every arm · 26 — 23-valent pneumococcal capsular polysaccharide vaccine is usual care beside what is tested
- Vaccine Responses in Patients With B Cell MalignanciesRecruitingPhase 4National Heart, Lung, and Blood Institute (NHLBI)NCT05170399Written as PNEUMOVAX 23
- Interleukin-1 Receptor Antagonist (IL-1RA) (ANAKINRA) IN SEVERE SYSTEMIC-ONSET JUVENILE IDIOPATHIC ARTHRITISCompletedPhase 2/3Institut National de la Santé Et de la Recherche Médicale, FranceNCT00339157Written as Pneumo23
- Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate VaccineCompletedPhase 1/2Beijing Zhifei Lvzhu Biopharmaceutical Co., LtdNCT06703203Written as 23-Valent pneumococcal polysaccharide vaccine
- Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab TherapyCompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT03069703Written as PPV23
- A Study on the Effect of Nipocalimab on Vaccine Responses in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT05827874Written as PPSV23
- Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody LevelsCompletedPhase 4Jena University HospitalNCT02637583Written as PPV23
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)CompletedPhase 3Merck Sharp & Dohme LLCNCT03565900Written as PNEUMOVAX™23
- Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)CompletedPhase 3Merck Sharp & Dohme LLCNCT03921424Written as PNEUMOVAX™23
- Immunogenicity Study of an Anti-pneumococcal Vaccination Strategy in Patients With Sickle Cells DiseaseCompletedPhase 2Assistance Publique - Hôpitaux de ParisNCT02274415Written as Vaccination with the polysaccharide vaccine (Pneumo 23 ®)
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)CompletedPhase 3Merck Sharp & Dohme LLCNCT03480802Written as PNEUMOVAX™23
- Immune Response to PNEUMOVAX 23 in Healthy Adults Receiving Efgartigimod IVCompletedPhase 1argenxNCT05163834Written as PNEUMOVAX 23
- Pneumococcal Vaccines in Patients With AsthmaCompletedPhase 4Mayo ClinicNCT03260790Written as PPSV23
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)CompletedPhase 3Merck Sharp & Dohme LLCNCT03480763Written as PNEUMOVAX™23
- A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected InfantsCompletedPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT00000829Written as Pneumococcal Vaccine, Polyvalent (23-valent)
- Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and OlderCompletedPhase 3GlaxoSmithKlineNCT02045836Written as Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)CompletedPhase 3Merck Sharp & Dohme LLCNCT03547167Written as PNEUMOVAX™23
- VACcination In Methotrexate Treated Rheumatoid Arthritis PatientsCompletedPhase 3University Hospital, MontpellierNCT01942174Written as Pneumo23 / Pneumovax
- Pneumococcal Adult-dose Ranging Immunization StudyCompletedPhase 1/2Kaiser PermanenteNCT00169234Written as Pneumovax 23
- A Study to Evaluate the Effects of Rituximab on Immune Responses in Subjects With Active Rheumatoid Arthritis Receiving Background MethotrexateCompletedPhase 2Genentech, Inc.NCT00282308Written as 23-valent pneumococcal polysaccharide vaccine
- Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.CompletedPhase 2BiogenNCT02097849Written as 23-valent pneumococcal polysaccharide vaccine
Showing 20 of 26.
As the comparator · 29 — what is tested is compared with 23-valent pneumococcal capsular polysaccharide vaccine
- Phase II Clinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate VaccineCompletedPhase 2Reinovax Biologics Co., LTDNCT06678620Written as PPSV23
- A Clinical Study of the V116 Vaccine for Children and Teenagers (V116-013)CompletedPhase 3Merck Sharp & Dohme LLCNCT06177912Written as PPSV23
- Safety and Immunogenicity of V116 in Adults With Increased Risk for Pneumococcal Disease (V116-008)CompletedPhase 3Merck Sharp & Dohme LLCNCT05696080Written as PPSV23
- Safety and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 50 Years of Age or Older (V116-010, STRIDE-10)CompletedPhase 3Merck Sharp & Dohme LLCNCT05569954Written as PPSV23
- Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)CompletedPhase 3Merck Sharp & Dohme LLCNCT05393037Written as PPSV23
- PhaseⅠClinical Trial of 24-valent Pneumococcal Polysaccharide Conjugate VaccineCompletedEarly Phase 1Jiangsu Province Centers for Disease Control and PreventionNCT07025876Written as PPV23
- Extension Safety and Immunogenicity Study of GPNV-001CompletedPhase 1/2GPN VaccinesNCT05982314Written as Pneumovax-23
- Clinical Trial of Recombinant Pneumococcal Protein VaccineCompletedPhase 1CanSino Biologics Inc.NCT05622942Written as PPV23
- Phase I Clinical Trial of PCV24 in People Aged 18 Years and OlderCompletedPhase 1Shanghai Reinovax Biologics Co.,LTDNCT06678607Written as PPSV23
- 20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and TaiwanCompletedPhase 3PfizerNCT04875533Written as PPSV23
- A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-experienced Adults (V116-006, STRIDE-6)CompletedPhase 3Merck Sharp & Dohme LLCNCT05420961Written as PPSV23
- Safety and Immunogenicity of V116 in Vaccine-naïve Japanese Older Adults (V116-009, STRIDE-9)CompletedPhase 3Merck Sharp & Dohme LLCNCT05633992Written as PPSV23
- A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)CompletedPhase 3Merck Sharp & Dohme LLCNCT05464420Written as PPSV23
- Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.CompletedPhase 1GPN VaccinesNCT05667740Written as Pneumovax-23
- A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal VaccineCompletedPhase 1/2GlaxoSmithKlineNCT03803202Written as PPSV23
- Safety, Tolerability, and Immunogenicity of a Polyvalent Pneumococcal Conjugate Vaccine (V116) in Japanese Adults (V116-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT04665050Written as PNEUMOVAX™23
- A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)CompletedPhase 1/2Merck Sharp & Dohme LLCNCT04168190Written as Pneumovax™23
- Evaluation of Safety and Immunogenicity of Combined Immunization of PPV23 and IIV4CompletedPhase 4China National Biotec Group Company LimitedNCT04559204Written as PPV23
- Trial to Evaluate the Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-naïve AdultsCompletedPhase 3PfizerNCT03760146Written as PPSV23
- Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal VaccinationCompletedPhase 3PfizerNCT03835975Written as PPSV23
Showing 20 of 29.